Title:Fluvoxamine; An antidepressant drug with anti-inflammatory and remyelination effects in acute experimental autoimmune encephalomyelitis rat as a model of monophasic multiple sclerosis
Name: Majid Gharghani
Yasuj University of Medical Sciences, Yasuj, Iran
Multiple sclerosis (MS) is associated with a neuropsychiatric problems of which depression is the commonest. Also Antidepressants are known to impact on the immune system and CNS cells. Aim of present study was to introduce drug with ameliorative effects in condition of depression, neuroinflammation and remyelination. In this study, first, we examined the effect of Fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), on proliferation and differentiation of embryonic neural stem cells (eNSCs) culture.Next, we studied it’s immunomodulatory and oligodendrogenesisproperties in experimental autoimmune encephalomyelitis (EAE) rat, an animal model of acute MS. Here, we showed that Fluvoxaminestimulates differentiation of eNSCs toward oligodendrocytein mice eNSCs culture.Subsequently, after induction of EAE, administration of Fluvoxamine demonstrated that itimproves neurologicaldeficits and significantly suppresses the secretion of IFN-γ and enhances IL-4 in serum, which it was coincidence by decline in lymphocyte infiltration and demyelination area of spinal cord using Hematoxylin-Eosin and Luxol Fast Blue, respectively. Immunohistochemical study (IHC) demonstrated increase in number of myelin basic protein cells (MBP+ cells) of spinal cord. Measurement of serum Lactic acid using High Performance Liquid Chromatography (HPLC) showed reduced concentration of lactatic acid which is considered sign of healing. In conclusion, Fluvoxamine treatment significantly increased proliferation and differentiation of eNSCs which are essential for remyelination process. Also it persistently alters neuroinflammation as well as oligodendrogenesisin EAE rats. Our data suggest that Fluvoxamine could be one of the recommended drugs for treatment depression in MS patient with anti-inflammatory and remyelination effectsm which needs further clinical studies.
Biography
Majid Gharghani is a last year student of master in clinical biochemistry with the bachelor of cellular and molecular biology. He is very interest to continue his advanced education for PhD in field of neuroimmunolgy and multiple sclerosis. Currently, he is a teaching and research assistant.
Presenting author details
Full name: Majid Gharghani
Contact number: +989365243706
Email:
Category: Oral presentation